ROSEN, A LEADING NATIONAL FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - The lead plaintiff must file a motion with the court by May 12, 2025, to represent other class members [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in recovering funds [3] Group 3: Case Allegations - The lawsuit alleges that Geron Corporation made false or misleading statements regarding the market potential of its drug RYTELO, leading to overstated business and financial prospects [4] - Specific claims include a lack of awareness among healthcare providers, a weekly monitoring requirement, and competition that would impair the drug's profitability [4] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [4]